scholarly journals LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models

2020 ◽  
Vol 31 (15-16) ◽  
pp. 863-880
Author(s):  
Weidong Xu ◽  
Yuefeng Yang ◽  
Zebin Hu ◽  
Maria Head ◽  
Kathy A. Mangold ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Mouse Models ◽  
Immune Checkpoint Inhibitor ◽  
Transforming Growth Factor ◽  
Checkpoint Inhibitor ◽  
Transforming Growth Factor Β ◽  
Inhibit Tumor Growth ◽  
Oncolytic Adenoviruses ◽  
Checkpoint Inhibitor Therapy

scholarly journals Mouse models of transforming growth factor β impact in breast development and cancer

2005 ◽  
Vol 12 (4) ◽  
pp. 749-760 ◽  
Author(s):  
R Serra ◽  
M R Crowley
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Tumor Progression ◽  
Mouse Models ◽  
Transforming Growth Factor ◽  
Normal Development ◽  
Transforming Growth Factor Β ◽  
Branching Morphogenesis ◽  
Breast Development ◽  
Normal Mammary Gland

It is now recognized that transforming growth factor β (TGF-β) is an important factor that regulates normal breast development as well as breast cancer. Genetically engineered mouse models have been used to determine the role and mechanism of TGF-β action in normal development and diseases of the breast. Using these models, it has been determined that TGF-β regulates many steps of normal mammary gland development including branching morphogenesis, functional differentiation, cell-lineage decisions, and involution. Effects of TGF-β on normal development are mediated through signaling in both the epithelial and stromal compartments. In cancer, mouse models have indicated that TGF-β has biphasic effects on tumor progression, acting as a tumor suppressor in early stages of cancer and promoting invasion and metastasis at later stages. In addition, TGF-β may play a role in tumor progression through effects on the microenvironment. Recently, experiments in several mouse models have suggested that antagonism of TGF-β signaling may provide a therapeutic target for late-stage breast cancer, blocking metastasis without detrimental side effects. In the future, genetically altered mice will be used to establish models of human breast disease providing opportunities to test strategies for disease prevention and treatment.

Versican G1 and G3 domains are upregulated and latent transforming growth factor-β binding protein-4 is downregulated in breast cancer stroma

Breast Cancer ◽  
2011 ◽  
Vol 19 (1) ◽  
pp. 46-53 ◽  
Author(s):  
Yuko Takahashi ◽  
Hiroko Kuwabara ◽  
Masahiko Yoneda ◽  
Zenzo Isogai ◽  
Nobuhiko Tanigawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Transforming Growth Factor ◽  
Binding Protein ◽  
Transforming Growth Factor Β ◽  
Cancer Stroma

Expression analysis of selected miR‐206 targets from the transforming growth factor‐β signaling pathway in breast cancer

2019 ◽  
Vol 120 (8) ◽  
pp. 13545-13553
Author(s):  
Mahnaz Seifi‐Alan ◽  
Ali Dianatpour ◽  
Lobat Geranpayeh ◽  
Reza Mirfakhraie ◽  
Mir D. Omrani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Signaling Pathway ◽  
Expression Analysis ◽  
Transforming Growth Factor ◽  
Transforming Growth Factor Β
Sign in / Sign up

Export Citation Format

Share Document